Bayer AG Bets $4 Billion on R8D and Sales From 5 Blockbuster Drugs

German pharmaceutical and chemical company Bayer AG (BAYN.XE) said Wednesday it sees peak annual sales potential of 5.5 billion euros ($7 billion) for its five new drugs Xarelto, Stivarga, Alpharadin, Aflibercept and Riociguat. Bayer now includes the new drug Riociguat, which helps to treat pulmonary hypertension, in its sales forecast. The company said late last year that it sees peak sales potential of at least EUR1 billion for the cancer drugs Alpharadin and Regorafenib, also known as Stivarga, as well as the eye medicine Aflibercept, also known as Eylea and VEGF Trap-Eye.